WP
RGLS

Woodline Partners’s Regulus Therapeutics RGLS Stock Holding History

Woodline Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-948,702
Closed -$1.49M – 983
2024
Q3 		$1.49M Buy
948,702
+1,017
+0.1% +$1.68K 0.01% 490
2024
Q2 		$1.69M Buy
+947,685
New +$2.2M 0.02% 435

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's RGLS Position: Q4 2024 in Review

Woodline Partners sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 948,702 shares — an estimated $1.49M sold.

Woodline Partners first reported a position in RGLS in Q2 2024 and held it in 2 quarters. The position peaked at $1.69M in Q2 2024. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

  • Woodline Partners reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 948,702 Regulus Therapeutics shares in Q4 2024, an estimated $1.49M.
  • Woodline Partners first reported a position in Regulus Therapeutics in Q2 2024 and held it in 2 quarters.
  • Woodline Partners's Regulus Therapeutics position peaked at $1.69M in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.